TIL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Instil Bio subsidiary halts clinical development of AXN-2510 and ends license and collaboration deal with ImmuneOncoJan 6, 2026
- Instil Bio receives FDA clearance of IND for AXN-2510, a PD-L1xVEGF bispecific antibody, for Phase 1 trial in relapsed/refractory solid tumorsJul 2, 2025
- Instil Bio and ImmuneOnco's Phase 2 trial in first-line NSCLC using PD-L1xVEGF bispecific antibody with chemo on track for full enrollment in Q3 2025, with results expected in 2H 2025May 22, 2025